Lonza released its Q3 « qualitative business overview » and held its investors day in the US. The Pharma&Biotech segment is said to enjoy continued strong performance in revenue and profitability while the Speciality Ingredients segment posts robust results thanks to portfolio management. The group upgraded its guidance for FY16 core EBIT growth, from a double-digit growth to « over 15% growth ».
27 Oct 2016
Q3 business overview: everything looks just fine!
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 business overview: everything looks just fine!
Lonza Group AG (0QNO:LON) | 0 0 0.0% | Mkt Cap: 22,735m
- Published:
27 Oct 2016 -
Author:
Fabrice Farigoule -
Pages:
2
Lonza released its Q3 « qualitative business overview » and held its investors day in the US. The Pharma&Biotech segment is said to enjoy continued strong performance in revenue and profitability while the Speciality Ingredients segment posts robust results thanks to portfolio management. The group upgraded its guidance for FY16 core EBIT growth, from a double-digit growth to « over 15% growth ».